You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
We’d love to keep you in the loop. Sign up to get updates on Gamifant® (emapalumab-lzsg) and advancements in the treatment of primary HLH.
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.1-4
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.5
Gamifant is given as an intravenous infusion twice a week until hematopoietic stem cell transplantation (HSCT) is performed.5
Download the Start Form now or contact Gamifant Patient Services at 833.597.6530.